Shares of Ventyx Biosciences (NASDAQ:VTYX) traded flat on Tuesday, even after the company released promising top-line results ...

Ventyx Biosciences has reported encouraging top-line outcomes from its single-centre Phase IIa trial of the central nervous ...

Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...

Ventyx Biosciences disclosed positive top-line results from its Phase 2a study of VTX3232 in patients with early-stage Parkinson's disease.

Jefferies analysts said on Tuesday that Ventyx could leverage its mid-stage data for VTX3232 to position the oral drug candidate as a treatment for other neurodegenerative diseases, including ...

In the last year, multiple insiders have substantially increased their holdings of Ventyx Biosciences, Inc. (NASDAQ:VTYX) stock, indicating that insiders' optimism about the company's prospects has ...

Ventyx Biosciences announced positive results from its Phase 2a study of VTX3232, an NLRP3 inhibitor, demonstrating safety and tolerability in patients with early-stage Parkinson's disease.

VTX3232 is a CNS-penetrant, potent and selective inhibitor of the NLRP3 inflammasome. VTX3232 has an excellent non-clinical in vitro and in vivo safety profile including in 6- and 9-month chronic ...

Ventyx Biosciences Inc (NASDAQ:VTYX), currently trading at $2.20 and considered undervalued according to InvestingPro analysis, announced results Tuesday from its Phase 2a trial of VTX3232 for ...

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

No acute changes in exploratory PET imaging were observed, consistent with a relatively short, 28-day study Ventyx intends to present the complete dataset at a future medical meeting and to ...